|Metabolism||Hepatic (including CYP2C9, CYP3A4 and CYP1A2)|
|Elimination half-life||1.5–1.7 hours|
|Excretion||Renal 73%, faecal 24%|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||294.351 g/mol g·mol−1|
|3D model (JSmol)|
It was patented in 1987 and approved for medical use in 2002. It is currently marketed by Prometheus Laboratories Inc. (San Diego). Alosetron was withdrawn from the market in 2000 owing to the occurrence of serious life-threatening gastrointestinal adverse effects, but was reintroduced in 2002 with availability and use restricted.
Alosetron is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS-D) who have:
- chronic IBS symptoms (generally lasting 6 months or longer),
- had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and
- not responded adequately to conventional therapy.
Severe IBS-D includes: diarrhea and 1 or more of the following:
- frequent and severe abdominal pain/discomfort,
- frequent bowel urgency or fecal incontinence,
- disability or restriction of daily activities due to IBS.
The phase III trial for approval was published in 2000 as an industry-funded randomised, placebo-controlled trial (PCT). Its authors found 1 mg alosetron, taken orally twice daily for 12 weeks, was associated with a 12% (CI 4.7-19.2) improvement in relief from abdominal pain and discomfort associated with diarrhoea-predominant patients. The prescription of alosetron is currently approved in the U.S. at 0.5 and 1 mg.
The FDA Medical Officer's Review, dated November 4, 1999, noted: “Patients considered by investigators to fit the diarrhea-predominant subtype had at baseline… stool consistency values that were neither loose nor watery”. The FDA's Gastrointestinal Drugs Advisory Committee referred to the drug's efficacy as "modest", highlighting that the placebo brought relief on the primary outcome measure to 40–50% of women.
Lotronex's prescribing information brochure states that alosetron should not be initiated in patients with constipation. Other contraindications are: history of chronic or severe constipation or sequelae from constipation; intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions, ischemic colitis, impaired intestinal circulation, thrombophlebitis, or hypercoagulable state; Crohn's disease or ulcerative colitis; diverticulitis; severe hepatic impairment. Concomitant use of fluvoxamine is also contraindicated.
Alosetron was withdrawn in 2000 following the association of alosetron with serious life-threatening gastrointestinal adverse effects. The cumulative incidence of ischaemic colitis was 2 in 1000, while serious complications arising from constipation (obstruction, perforation, impaction, toxic megacolon, secondary colonic ischaemia, death) was 1 in 1000. A 1999 review performed by FDA medical officer John Senior, indicated that 27% of patients experienced constipation. The phase III trial reported constipation occurred in 30% and 3% of patients in the alosetron and placebo groups, respectively. It was cited as the most important reason for patients dropping out of the study.
Mechanism of action
Alosetron has an antagonist action on the 5-HT3 receptors of the enteric nervous system of the gastrointestinal tract. While being a 5-HT3 antagonist like ondansetron, it is not classified or approved as an antiemetic. Since stimulation of 5-HT3 receptors is positively correlated with gastrointestinal motility, alosetron's 5-HT3 antagonism slows the movement of fecal matter through the large intestine, increasing the extent to which water is absorbed, and decreasing the moisture and volume of the remaining waste products.
Alosetron was originally approved by the U.S. Food and Drug Administration (FDA) on February 9, 2000, after a seven-month review. At the time of the initial approval U.S. Food and Drug Administration (FDA) reviewers found that alosetron improved symptoms in 10% to 20% of patients.
Shipment to pharmacies started in March, 2000. On July 17, a health professional filed a report with the FDA on the death of a 50-year-old woman who suffered mesenteric ischemia. The report identified alosetron as the "primary suspect" in the death.
Alosetron was withdrawn from the market voluntarily by GlaxoWellcome on November 28, 2000 owing to the occurrence of serious life-threatening gastrointestinal adverse effects, including 5 deaths and additional bowel surgeries. The FDA said it had reports of 49 cases of ischemic colitis and 21 cases of "severe constipation" and that ten of the 70 patients underwent surgeries and 34 others were examined at hospitals and released without surgery. Through November 17, 2000, pharmacists had filled 474,115 prescriptions for alosetron. Severe adverse events continued to be reported, with a final total of 84 instances of ischaemic colitis, 113 of severe constipation, 143 admissions to hospital, and 7 deaths.
Patient advocacy groups, most notably the Lotronex Action Group and the International Foundation for Functional Gastrointestinal Disorders (IFFGD) lobbied for the drug's return. Public Citizen Health Research Group, another patient advocacy group, opposed the reintroduction.
On June 7, 2002, the FDA announced the approval of a supplemental New Drug Application (sNDA) that allows restricted marketing of Lotronex (alosetron hydrochloride), to treat only women with severe diarrhea-predominant irritable bowel syndrome (IBS). The strict prescribing guidelines initially introduced in 2002 were relaxed slightly in 2016, enabling electronic prescriptions among other benefits.
It is not known whether alosetron has been filed for registration in the EU.
Since 2015, generic versions of alosetron have been available in the US, sold by a number of different companies including Actavis Pharma Company, Prometheus Laboratories and Sebela Pharmaceuticals Inc
Criticism of the FDA
In 2001, the editor of the renowned medical journal The Lancet, Richard Horton, criticized the FDA's handling of alosetron in an unusually sharp language. Horton argued that the treatment of a non-fatal condition did not justify the use of a drug with potentially lethal side effects, and that the FDA should have revoked the approval for alosetron sooner when postmarketing surveillance revealed that many patients had suffered constipation necessitating surgical intervention and ischaemic colitis. He asserted that FDA officials were improperly motivated to maintain and reinstate the approval for alosetron because of the extent to which the FDA's Center for Drug Evaluation and Research is funded by user fees paid by pharmaceutical manufacturers, and that the reinstatement of alosetron was negotiated in confidential meetings with representatives of GlaxoSmithKline.
An article published in the British Medical Journal (BMJ) noted: "By allowing the marketing of alosetron, a drug that poses a serious and significant public health concern according to its own terms, the FDA failed in its mission." Others have argued that the approval process of Lotronex was an example of regulatory capture.
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 448. ISBN 9783527607495.
- "Lotronex (alosetron hydrochloride) Tablets. Full Prescribing Information" (PDF). Prometheus Laboratories Inc., 9410 Carroll Park Drive, San Diego, CA 92121. Retrieved 14 February 2016.
- Camilleri, M.; Northcutt A.R.; Kong S.; Dukes G.E.; McSorley D.; Mangel A.W. (25 March 2000). "Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial". The Lancet. 355 (1035): 1035–40. doi:10.1016/S0140-6736(00)02033-X. PMID 10744088.
- Moynihan, Ray (14 September 2002). "Alosetron: a case study in regulatory capture, or a victory for patients' rights?". The British Medical Journal. 325 (7364): 592–595. doi:10.1136/bmj.325.7364.592. PMC 1124108. PMID 12228140.
- Barbehenn, Elizabeth; Peter Lurie; Sidney M. Wolfe (9 December 2000). "Alosetron for irritable bowel syndrome". The Lancet. 356 (9246): 2009. doi:10.1016/S0140-6736(05)72978-0. Retrieved 11 December 2012.
- Willman, David (2 November 2000). "FDA Minimized Issue of Lotronex's Safety". The Los Angeles Times. Retrieved 11 December 2012.
- U.S. Food and Drug Administration. "Drug Details". Retrieved 11 December 2012.
- Willman, David (29 November 2000). "Drug Lotronex Pulled Over Safety Fears". The Los Angeles Times. Retrieved 11 December 2012.
- Willman, David (20 December 2000). "Officer Foresaw Deadly Effects". The Los Angeles Times. Retrieved 11 December 2012.
- Center for Drug Evaluation and Research (23 April 2002). "Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Subcommittee of the Advisory Committee for Pharmaceutical Science" (PDF). U.S. Food and Drug Administration. Retrieved 11 December 2012.
- Grady, Denise (23 April 2002). "Appeals Prompt U.S. Agency to Consider Allowing Sales of Diarrhea Drug Linked to Deaths". The New York Times. Retrieved 11 December 2012.
- Pollack, A (2006-03-09). "F.D.A. Panel Recommends M.S. Drug Despite Lethal Risk". The New York Times. Retrieved 2008-03-13.
- Grady, Denise (8 June 2002). "U.S. Lets Drug Tied to Deaths Back on Market". The New York Times. Retrieved 11 December 2012.
- Prometheus Laboratories Inc. Press Release of 7 November 2007. Archived 2012-07-14 at Archive.today Retrieved on 27 August 2008.
- Horton, R. (2001). "Lotronex and the FDA: a fatal erosion of integrity". The Lancet. 357 (9268): 1544–45. doi:10.1016/S0140-6736(00)04776-0. PMID 11377636.
- Lièvre, Michel (14 September 2002). "Alosetron for irritable bowel syndrome". The British Medical Journal. 325 (7364): 555–556. doi:10.1136/bmj.325.7364.555. PMC 1124090. PMID 12228116.